Comparative Analysis of B-Cell Receptor Repertoires Induced by Live Yellow Fever Vaccine in Young and Middle-Age Donors

Alexey N. Davydov, Anna S. Obraztsova, Mikhail Y. Lebedin, Maria A. Turchaninova, Dmitriy B. Staroverov, Ekaterina M. Merzlyak, George V. Sharonov, Olga Kladova, Mikhail Shugay, Olga V. Britanova, and Dmitriy M. Chudakov

Age-related changes can significantly alter the state of adaptive immune system and often lead to attenuated response to novel pathogens and vaccination. In present study we employed 5′RACE UMI-based full length and nearly error-free immunoglobulin profiling to compare plasma cell antibody repertoires in young (19–26 years) and middle-age (45–58 years) individuals vaccinated with a live yellow fever vaccine, modeling a newly encountered pathogen. Our analysis has revealed age-related differences in the responding antibody repertoire ranging from distinct IGH C DR3 repertoire properties to differences in somatic hypermutation intensity and efficiency and antibody lineage tree structure. Overall, our findings suggest that younger individuals respond with a more diverse antibody repertoire and employ a more efficient somatic hypermutation process than elder individuals in response to a newly encountered pathogen.

Keywords: immunoglobulin repertoire, vaccination, age, yellow fever, plasma cell

INTRODUCTION

A number of previously published studies suggests that the function of adaptive immunity is impaired in aged individuals (1, 2). The findings include functionally exhausted immune repertoire displaying a substantially lower diversity of T cell and B cell receptors compared to young individuals (3–6), impaired antigen-driven selection mechanisms (7, 8), and attenuated response to vaccines (9–16).

Functional defects of antibody-mediated vaccine-induced immunity in elderly adults are manifested both in the hampered generation of a primary response and in decreased effect of booster vaccination: low production of vaccine-specific antibodies, low affinity and opsonic capacity of generated antibodies, reduced vaccine longevity (9, 13, 14, 17–23). Altogether, this leads to lower protection achieved in the elderly than in young adults. However, the exact reasons of poor vaccine response in old people have not been fully elucidated.
Recent advances in high-throughput sequencing (HTS) allow performing a targeted readout of hundreds of thousands of B-cell receptor (BCR) heavy chain (IGH) sequences from samples of interest (24–30), providing a powerful tool for investigation of age-related changes in B cell immunity. HTS profiling of BCR repertoires reveals contracted clonal diversity both in naïve and antigen-experienced B memory subsets, and accumulation of highly mutated immunoglobulin genes and persistent clonal expansions with aging (25, 31, 32). The latter resembles the age-related changes in T cell repertoire (5, 33–35), and altogether these effects can be linked to the decreased efficiency of vaccination in the elderly adults (32, 34, 36).

The HTS approach was also employed for studies of influenza (25, 27), tetanus (37), and hepatitis B (38, 39) vaccines. It was demonstrated that B cell repertoire has the ability to rapidly expand and contract in a highly dynamic mode in response to vaccination (27). Stereotypic changes of B cell repertoires include increase in mutation frequency and decrease in diversity 4–10 days after vaccination, which corresponds to the maximum concentration of mutated plasma cells released into the peripheral blood (38–40). Interestingly, highly homologous “public” BCR variants can be produced in response to the same antigen in different individuals by convergent recombination and selection (27, 41, 42).

There is also an increasing number of data characterizing changes in the antibody repertoires with respect to vaccine immune stimulus and age. We have found three HTS-based studies of BCR repertoires aimed at revealing the age-related differences in vaccine response, all tracking the changes upon influenza vaccine challenge (25, 32, 43).

Wu et al. (43) analyzed cDNA-based BCR repertoires obtained from the peripheral blood mononuclear cells (PBMC) of young (19–25 years) and old (70–89 years) individuals, where responding B cell clones (groups of homologous clonotypes) could be distinguished by their large size at D7 in terms of the number of included clonotypes. In the old individuals, they reported decreased average clone size within IgA isotype, and increased CDR-H3 length and lower mutation frequency for the large IgA and IgM clones.

Jiang et al. (25) analyzed cDNA-based BCR repertoires obtained from PBMC of 8–17, 18–32, and 70–100 years old groups of individuals at D0, D7–8, and D28 (±4) after vaccination. At D7–8, plasmablasts were sorted as CD3–CD19+CD27highCD38high plasma B cells from peripheral blood samples obtained from healthy volunteers 9 days after their first vaccination with live YF vaccine. In this time frame, the concentration of plasma B cells in peripheral blood increases dramatically and mainly represents the cells that respond specifically to the vaccine antigens (40, 48).

It should be noted, that a minor portion of peripheral blood plasma B cells analyzed 9 days after vaccination could include clones responding to the current antigens other than the YF, such as self-antigens and antigens arising from commensal microorganisms or chronic infections. Thus the picture of the differences observed in the plasma B cell repertoires of young and middle-age donors after YF immunization could include imprint from the general differences in the ongoing plasma B cell response between the young and middle-age volunteers, as well as differences in memory-track prehistory of these responses. According to our observations, 9 days after YF vaccination, relative abundance of plasma B cells in peripheral blood increased more than 10-fold and reached 15.5% ± 10% of CD19+CD27high B cells (Supplementary Figure 1), similar for both age groups, which corresponds well to the previous data with influenza vaccination (48). Thus we estimate the contribution of such non-YF vaccination related B cell clones as ∼10% of the analyzed cDNA quantity.

It should be also noted that since our approach to immunoglobulin profiling is RNA-based, the resulting IGH repertoires yield the picture that intrinsically accounts for the difference in the IGH mRNA expression levels, thus favoring B cell clones with high production of immunoglobulins.

In our data analysis, we have focused on three groups of variables that together provide a comprehensive repertoire characterization:
1) V-D-J rearrangement structure and CDR3 physicochemical properties;
2) Antibody lineage structure (clonal trees);
3) Profiles of newly acquired and potentially pre-existing somatic hypermutations.

We reveal a number of antibody repertoire features that were distinct between young and middle-age individuals, highlighting age-related differences in humoral immune response directed against newly encountered antigens, that are already detectable by the age of 50.

METHODS

Blood Donors and Samples

This study was approved by the local ethical committee and conducted in accordance with the Declaration of Helsinki. All donors were informed of the final use of their blood and signed an informed consent document. The cohort of healthy donors (n = 10, Table 1) has been immunized for the first time by the yellow fever vaccine (live freeze-dried preparation of the 17D strain of YFV licensed in Russia, FSUE of Chumakov IPVE, RAMS). Yellow fever is not endemic in Russia and the volunteers have not previously traveled to areas known to be endemic for yellow fever. Peripheral blood (9 ml per sample) was collected on the 9th day after vaccination into EDTA-treated Vacutainer tubes (BD Biosciences). The B cells were stained for surface markers by incubating with following monoclonal antibodies: CD38-PE (BD Biosciences), CD20-Vio Blue (clone LT20, Miltenyi Biotec), CD27-PC5 (clone HB7, eBioscience), CD19-FITC (clone J3-119, Beckman Coulter), CD20-CD19

RNA Extraction, cDNA Libraries Preparation, and Sequencing

UMI-barcoded IGH cDNA libraries for the vaccinated donors were prepared as described previously (44) with minor modifications which allow to introduce Illumina Nextera adapters and indexes during PCR. Briefly, total RNA was extracted from sorted B cells using RNeasy Micro Kit (QIAGEN) and converted to cDNA using 5′ template switch adapter containing UMI. The cDNA was treated with UDG (NEB), and purified using AMPure Beads (Beckman Coulter). A portion of cDNA equivalent to 200 sorted plasma B cells (Table 1) was used for further PCR amplification. Appropriate amount of cDNA used for the library preparation is critical in order to achieve sufficient coverage in terms of sequencing reads per UMI, which is a prerequisite for the efficient error correction (44–46). IGH libraries were amplified using a set of IGHC-specific and 5′ template switch adapter-specific primers introducing indexed Nextera sequencing adapters. Please refer to the Table 2 for the oligonucleotides used. The resulting libraries were analyzed on 2 runs of Illumina MiSeq, paired-end 310+310 nt sequencing. All 10 samples were analyzed within each run, and results of the 2 runs were pooled before further bioinformatic analysis.

Data Preprocessing and Analysis

UMI extraction and UMI-based consensus assembling was performed using MIGEC software (45), with a 5 reads-per-UMI threshold. Further reads mapping and clonotypes (unique full length IGH nucleotide sequences) assembling was performed using MiXCR as described previously (44) with some changes in MiXCR analysis pipeline (KAligner alignment algorithm was used that allows to detect indels of more than 2 nt). Resulting clonerset deposited at https://figshare.com/articles/Comparative_analysis_of_B-cell_receptor_repertoires_induced_by_live_yellow_fever_vaccine_in_young_and_middle_age_donors/6853961.

All analyses except for depicted in Figure 5A were performed using mean values for repertoire features and summary statistics computed for each donor, statistical testing was performed by comparing values for n = 5 young and n = 5 middle-age donors.

Antibody Lineage Analysis

Reconstruction of clonal trees was done using in-house algorithm that takes into account VJ assignment and NDN sequence of IGH and can be briefly described as follows. First, IGH clonotypes are

| TABLE 1 | Donor and sample metadata. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Donor ID | Age range (median), years | Status | Number of sorted plasma cells | Portion of cDNA used | Number of raw paired-end sequencing reads | Number of analyzed IGH cDNA molecules | Number of unique IGH clonotypes extracted |
| P1 | 19–26 (19) | Young | 6,000 | 1/30 | 4,410,583 | 29,052 | 3,913 |
| P2 | 6,000 | 1/30 | 3,443,963 | 17,284 | 3,590 |
| P3 | 6,000 | 1/30 | 2,566,472 | 11,154 | 1,761 |
| P4 | 6,000 | 1/30 | 4,410,583 | 21,879 | 2,507 |
| P5 | 6,000 | 1/30 | 2,888,569 | 18,086 | 2,563 |
| P6 | 45–58 (55) | Middle-age | 6,000 | 1/30 | 1,939,674 | 19,111 | 2,529 |
| P7 | 6,000 | 1/30 | 3,133,844 | 42,768 | 3,520 |
| P8 | 6,000 | 1/30 | 2,731,660 | 21,879 | 2,507 |
| P9 | 6,000 | 1/30 | 2,566,472 | 11,154 | 1,761 |
| P10 | 6,000 | 1/30 | 1,845,910 | 20,102 | 2,427 |
| Primer                      | Application                                                                 | Sequence                                                                 |
|----------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------|
| SmartNNNext                | 5′-template-switch oligo with sequencing illumina adapter                   | AGATGUGTAUAAGACAGCAAGNNNNUNNNNUNNUUGCTT(rG)4                             |
| **IGH cDNA synthesis primer mix** |                                                                             |                                                                         |
| hiGG_r1                    | Primer for cDNA synthesis, human IgG heavy-chain mRNA                       | GAAGTAGGCTCGGGAGAAAGAGAAG                                                |
| hiGM_r1                    | Primer for cDNA synthesis, human IgM heavy-chain mRNA                       | GTGAGGTGACGCGAGAAAGAGAAG                                                  |
| hiGA_r1                    | Primer for cDNA synthesis, human IgA heavy-chain mRNA                       | GCGAGGACGCGAGTCCCGCATCT                                                  |
| hiGD_r1                    | Primer for cDNA synthesis, human IgD heavy-chain mRNA                       | GACACCAGGCGTGTTATGC                                                     |
| hiGE_r1                    | Primer for cDNA synthesis, human IgE heavy-chain mRNA                       | AGTCACGAGGCGTGCGATT                                                     |
| **FIRST PCR AMPLIFICATION** |                                                                             |                                                                         |
| Common primer              | Step-out primer, anneals on the switch adapter                              | AGATGTTATAAGAGACAG                                                       |
| **IGH reverse primer mix** |                                                                             |                                                                         |
| Common-hIGGE_r2            | Nested primer with sequencing illumina adaptor, human IgG/EG heavy-chain cDNA| AGATGTTATAAGAGACAGAGGGAAGACGAGT                                             |
| Common-hIGA_r2             | Nested primer with sequencing illumina adaptor, human IgA heavy-chain cDNA   | AGATGTTATAAGAGACAGAGGGAAGACGAGT                                             |
| Common-hIGM_r2             | Nested primer with sequencing illumina adaptor, human IgM heavy-chain cDNA   | AGATGTTATAAGAGACAGAGGGAAGACGAGT                                             |
| Common-hIGD_r2             | Nested primer with sequencing illumina adaptor, human IgD heavy-chain cDNA   | AGATGTTATAAGAGACAGAGGGAAGACGAGT                                             |
| **SECOND PCR AMPLIFICATION** |                                                                             |                                                                         |
| F-common                   | Step-out primer with sequencing and P7 illumina adapters                    | TCGTCGGCAGCGGTGATTATAGGAGACAGCAG                                           |
| R-common                   | Step-out primer with sequencing and P5 illumina adapters                    | GTCTCGTGGCGTCGGAGATGTTATAGGAGACAGCAG                                           |
| **THIRD PCR AMPLIFICATION** |                                                                             |                                                                         |
| Fc_i7^a                    | Step-out primer with index 1 illumina adapter                               | CAACAGAAGACGGATACAGGAT[7]GTCTCGTGGCGTCGG                                     |
| Fc_i5^b                    | Step-out primer with index 2 illumina adapter                               | AATGATACGGCGACACGAGAGATGCAC[5]TCGTCGGCAGCGGTTC                                   |

^a,b: Illumina Nextera index adapters (i5 and i7). See illumina Nextera DNA library preparation reference guide and illumina adapters sequences list for more information.

clustered into groups containing sequences with matched V and J segments. Then, a pairwise comparison is performed for each group: if the K-mer (K = 5) composition of NDN regions of two sequences is highly similar the sequences are considered to originate from one ancestor sequence and connected by an edge on the lineage tree.

An edge connects a pair of clonotypes that are likely to come from a pair of cells, one of which is a hypermutated [bears a B-cell receptor with mutation(s)] sub-variant of another. The direction of edge shows which of the clonotypes is a parent one and which is a child one. As we use full-length immunoglobulin sequencing data, one can infer edge direction using parsimony principle: parent clonotype mutations should be a subset of child mutations.

The similarity is computed by summing the information content of each K-mer (that is, the logarithm of its probability to be found in random VDJ rearrangements), thus K-mers containing many non-template bases are scored the most. The similarity score threshold for drawing an edge was selected according a benchmark performed by in-silico mixing Raji hypermutating cell line repertoire and PBMC IGH samples. CDR3 hypermutations were obtained using Smith-Waterman alignment for each pair of connected nodes with different CDR3 sequences. Parsimony principle was applied to remove improbable nodes and infer the direction of edges. In order to eliminate duplicate paths and form a tree structure we next removed all incoming edges except the one with lowest number of mutations. To normalize samples for accurate comparison, we extracted 10,000 randomly sampled IGH cDNA molecules from each dataset.

### CDR3 Physicochemical Property Analysis

Averaged CDR3 physicochemical properties of repertoires accounting for the clonotypes size were computed using custom R script. To estimate the energy of the interaction between CDR3 and a random epitope, we used Miyazawa-Jernigan statistical potential (49), that is based on calculating the frequencies of certain amino acids being in close proximity with each other in available structural data, and assuming that these frequencies follow Boltzmann distribution parameterized by corresponding energy values. For each amino acid among the five positions in the middle of CDR3, we computed the average interaction energy with all 20 amino acids. We then summed values across amino acid residues to estimate the energy of the interaction between CDR3 and a random epitope. Other physicochemical properties were analyzed similarly.

### Selection Strength

The selection strength was estimated using BASELINe framework (50) which compares the observed frequencies.
of replacement and silent mutations with the expected ones. BASELINe was applied to a subset of Variable segment sequences (FR1-FR3) that do not contain indels and the closest germline alleles as a reference. For each donor, clonal groups of sequences were collapsed to consensus sequences using SHazaM R package (51) as recommended by BASELINe authors. The probability density functions of the selection strength were compared using built-in statistical test.

RESULTS

CDR3 Characteristics

Analysis of the averaged CDR3 characteristics was performed for IgA, IgG, and IgM isotypes, weighted by the abundance of each clonotype (i.e., the input of each clonotype was proportional to its frequency within repertoire), and included CDR3 length, added N nucleotides, and physicochemical characteristics for the five amino acid residues located in the middle of CDR3 [having the highest probability to contact with antigen, by analogy with TCRs, (52)]. The latter included averaged statistical potential of CDR3:epitope interactions [the estimated “energy” of interaction between CDR3 and a random epitope (49)], “strength” of interaction [derivative of “energy,” VDJtools (53)], hydrophobicity (Kidera factor 4) (54, 55), and “volume” (VDJtools, values from: http://www.imgt.org/IMGTeducation/Aide-memoire/_UK/aminoacids/IMGTclasses.html) for the young versus middle-age individuals (see Table 3 for the values used for each amino acid property).

The analysis revealed several features that significantly differed between the responding plasma cell IGH repertoires of the two age groups but not between the isotypes (Figure 1). Of note, differences in “energy,” and hydrophobicity (Kidera factor 4) were previously demonstrated to be critical for antibody affinity and specificity (56). Altogether, observed differences indicated that middle-age individuals tend to respond to a new challenge with IGH variants carrying longer CDR3s [in agreement with (43)], with higher content of bulky, hydrophobic, and strongly interacting amino acid residues in the middle of CDR3.

Isotype and IGHV Gene Segments Usage

We have not detected prominent differences in IGHV gene segment usage as well as in isotype usage between plasma cell IGH repertoires of young and middle-age individuals vaccinated with YF (Figures 2A,B). The list of most commonly used IGHV segments included the IGHV4 (IGHV4-31, IGHV4-34, IGHV4-59, and IGHV4-39) family, IGHV3 (IGHV3-74, IGHV3-30, IGHV3-53, IGHV3-24) family, as well as IGHV1-18 and IGHV5-51.

Note that potential biases in isotype and IGHV gene segment usage are corrected by UMI-based analysis, since sequencing reads that cover the same cDNA molecule (irrespective to the efficiency of amplification of each particular isotype or gene segment) are clustered together, each cDNA molecule to a single UMI-labeled group of sequencing reads.

Differences in Immunoglobulin Clonal Lineage Structure

The analysis of antibody repertoires can be extended by grouping IGH clonotypes into clonal lineages (trees) that share a common ancestor (57) and represent a B-cell clone undergoing the affinity maturation process. UMI-based full-length immunoglobulin sequencing (44) and dedicated antibody tree building algorithm (see section Methods) allowed us to accurately infer and analyze clonal lineage structure.

This analysis revealed that basic graph characteristics, such as the Gini inequality coefficient, and number of singletons (clones including only one clonotype) were significantly different between young and middle-age YF-vaccinated donors (Figure 3A). The Gini coefficient measures the inequality of tree size (number of nodes) distribution. Large Gini coefficient values mean that large trees with many mutated variants dominate over small trees, i.e., most of the observed immunoglobulin variants come from few B-cell clones. Smaller values mean that more distinct clones enter the affinity maturation process during an immune response. Thus the direction of the observed differences suggests that young individuals have a more diversified responding repertoire, while middle-age individuals display a more biased lineage architecture with larger trees that account for the majority of observed clonotypes (Figures 3B,C).

Note that the trees may include impossible lineage relations such as IgA to IgM isotype conversion. This reflects the fact that our analysis is limited by sampling depth and particular time point. We do not observe the whole pre-history of hypermutation process, thus additional unseen IGH sequence variants that can

| Table 3 | Values used for CDR3 amino acid properties calculation. |
| Amino acid | Menergy | Kf4 | Volume | Strength |
|-----------|---------|-----|--------|---------|
| A         | -2.8455 | -0.27 | 67     | 0       |
| C         | -3.782  | -1.05 | 86     | 0       |
| D         | -2.116  | 0.81  | 91     | 0       |
| E         | -2.141  | 1.17  | 109    | 0       |
| F         | -5.017  | -1.43 | 135    | 1       |
| G         | -2.499  | -0.16 | 48     | 0       |
| H         | -2.927  | 0.28  | 118    | 0       |
| I         | -4.641  | -0.77 | 124    | 1       |
| K         | -1.789  | 1.7   | 135    | 0       |
| L         | -5.023  | -1.1  | 124    | 1       |
| M         | -4.1915 | -0.73 | 124    | 1       |
| N         | -2.349  | 0.81  | 96     | 0       |
| P         | -2.443  | -0.75 | 90     | 0       |
| Q         | -2.2505 | 1.1   | 114    | 0       |
| R         | -2.402  | 1.87  | 148    | 0       |
| S         | -2.308  | 0.42  | 73     | 0       |
| T         | -2.6145 | 0.63  | 93     | 0       |
| V         | -4.093  | -0.4  | 105    | 1       |
| W         | -4.1375 | -1.57 | 163    | 1       |
| Y         | -3.7505 | -0.56 | 141    | 1       |
FIGURE 1 | CDR3 characteristics. (A) CDR3 length, aa. (B) Number of non-template added N nucleotides within V-D-J junction. (C) Physicochemical properties for the 5 amino acids residues in the middle of CDR3: Kidera factor 4 (hydrophobicity, lower values refer to more hydrophobic amino acids), potential “energy” of interaction (49) (lower values refer to stronger interaction), “strength” and “volume.” All characteristics were calculated “weighted”—i.e., accounting for IGH clonotype size. ANOVA p-values for age and for isotype adjusted using Benjamini & Hochberg correction are shown on top of each plot.

FIGURE 2 | Isotype and IGHV segments usage for YF-vaccinated subjects from the two age groups. (A) Isotype usage. (B) IGHV usage.
(resolved this ambiguity may exist, e.g., unseen IgM sequence variant parent to observed IgM and IgA variants.

**Bulk Analysis of Somatic Hypermutations**

Bulk load of somatic hypermutations per clonotype obtained without using the information on the trees structure was comparable between young and middle-age plasma cell IGH repertoires ([Figure 4A](#)). We controlled for isotype which is necessary in such comparisons as there are substantial differences between base mutation burden for each isotype (e.g., mean number of SHMs in an IgG clonotype is about 2 times higher than per IgM clonotype).

In order to estimate the burden of somatic hypermutations that could earlier accumulate within memory B cells clones currently participating in immune response, we analyzed the frequency of hypermutations within the identified roots of the trees—the IGH sequence variants that were closets to germline within each tree. This analysis also has not revealed significant differences between the young and middle-age individuals in a load of root somatic hypermutations, potentially pre-existing within responding IGH clones ([Figure 4B](#)).

To test for the intrinsic differences in the structure of hypermutations, we estimated the average “selection strength” that drived the accumulation of somatic hypermutations in young versus middle-age individual repertoires using BASELINe framework ([50](#)), which is based on estimation of expected versus observed frequencies of replacement and silent mutations. This analysis indicated higher “selection strength” in the young versus middle-age individual IGH repertoires ([Figure 4C](#)).

**Observed History of Ongoing Somatic Hypermutations**

Finally, we focused on the newly generated mutations that are directly observed (identified in the edges of the trees), i.e., hypermutations that are supported by both observed “parent” and “child” clonotypes in the dataset. A dedicated tree building algorithm allowed us to infer the set of currently ongoing hypermutations on the entire length of the immunoglobulin sequence ([Figure 5A](#)). Note that in the full length analysis of clonal IGH evolution, we are able to identify all hypermutations that occurred within V gene segment, by comparing with the germline. For CDR3 region, we are only able to identify those mutations that differentiate the evolving clones from the identified root. We cannot determine the exact original CDR3 sequence that was generated during IGH recombination and thus cannot identify the hypermutations that have not been sampled by our analysis. This explains the lower proportion of hypermutations observed with CDR3 compared to CDR1 and CDR2 regions.

Middle-age individuals had higher total numbers of the newly acquired unique somatic hypermutations ([Figure 5B](#)), while the replacement-to-silent (R:S) ratio among such hypermutations was significantly lower compared to the young donors ([Figures 5C,D](#)).

**DISCUSSION**

Our comparative analysis of immune response to a novel pathogen, performed using immune repertoire sequencing and modeled by a live YF vaccine, revealed several differences between the two age groups indicating that humoral adaptive response already undergoes significant changes by the age of 50.

First, physicochemical properties of the hypervariable IGH CDR3 region that are linked to antigen recognition ([58](#), [59](#)) changed significantly ([Figure 1](#)). Differences in the interaction “energy,” Kidera factor 4, "strength" and "volume" indicate the increase of relative number of bulky, hydrophobic and strongly interacting amino acid residues in the middle of CDR3 with aging, potentially associated with increased cross-reactivity ([60](#)). In agreement with Wu et al. ([43](#)), responding repertoire of the middle-age donors also displayed longer CDR3s.

Second, the analysis of clonal lineages suggests that young individuals produce a more diverse IGH repertoire implying
FIGURE 4 | Bulk analysis of somatic hypermutations. (A) Somatic hypermutations per clonotype, without using trees information (NS, ANOVA). (B) Somatic hypermutations within roots of the trees with >2 nodes (NS, ANOVA). (C) Selection strength estimated using BASELINE framework. Adjusted $p = 0.011$ for CDR, 0.011 for FWR.

FIGURE 5 | Patterns of newly acquired somatic hypermutations in young and middle-age donors vaccinated with YF. (A) Summary profile of somatic hypermutations observed in the study. IGH regions are marked with color. The distribution of silent (S) and replacement (R) hypermutations are shown with dashed and solid lines, respectively. For CDR3 region, mutation analysis was done using the root as reference. Data were pooled for all young and all middle-age individuals. (B) Frequency of newly acquired somatic hypermutations (SHMs) in young (red) and middle-age (blue) donors. ANOVA $p = 0.0005$ for age, 0.14 for isotype. (C,D) Mean replacement:silent ratio (R:S ratio) for newly acquired somatic hypermutations (SHMs) in young and middle-age donors, for isotypes (C, ANOVA $p = 0.058$ for age, 0.69 for isotype) and regions (D, ANOVA $p = 0.0013$ for age, 0.00014 for regions).
higher efficiency of the adaptive immune response (61). Middle-age individuals responded to YF vaccination with higher proportion of clonal hypermutating B cell trees of a larger size (Figure 3), which echoes the observation that elderly individuals have generally decreased numbers of B-cell lineages (25). Older individuals responded with lower lineage diversity, for which general decrease of B cell diversity with aging, correlating with the health status, could be one of the reasons (6, 62).

While the exact reason behind the observed differences in the structure of IGH repertoire responding to novel antigens in young and middle-age individuals is unknown, one can speculate that they could be attributed to overall decrease in circulating B cells (63, 64), including memory B cells that initially recognized unrelated antigens but could respond to YF vaccination, decreased production and counts of naive B-cells (65, 66) and their diminished ability to enter somatic hypermutation (66, 67). All these factors narrow the capability of B cell immunity to select novel immunoglobulin variants.

Third, responding clonal lineages of the middle-age individuals hypermutated more intensely (Figure 5B) but less efficiently in terms of replacement-to-silent mutations ratio compared to young individuals (Figures 4C, 5C,D). The latter result overlaps with previous works, which show that loss of functional repertoire diversity is determined by not only the reducing the number of different B cell lineages but also by decreased proportion of replacement mutations (68) and mutations prominently changing the amino acid properties (32). This observation suggests that the parameters of affinity maturation may essentially vary between young and middle-age individuals, and is in line with previous works demonstrating impaired ability to produce high affinity protective antibodies against newly encountered antigens in the older individuals (13), and general changes in the mechanisms of IGH affinity maturation and memory B cells generation with aging (66).

Of note, it was earlier demonstrated that AID levels and intensity of hypermutation decrease with aging, but only after the age of 60 (63, 69, 70)—beyond the age of the cohorts that we have studied in the current work.

We have not obtained data on serum titers of YF-specific antibodies due to technical unavailability of samples. In general, it is known that the serum titers are similar for these age groups (71, 72), and are sufficiently high to provide protection for many years: (73). Thus the observed differences in the B cell response to the live YF vaccine between young and middle-age individuals are not detrimental for generation of protective immunoglobulin repertoire. However, these differences reveal the dynamics of changes in humoral response architecture that are already detectable by the age of 50 years.

Further studies involving a larger set of novel antigens and comprehensive longitudinal tracking of the response, as well as studies of vaccinations with vaccine boost, can shed more light on the fine properties of age-related changes in B cell response.

AUTHOR CONTRIBUTIONS

DS and GS performed cell sorting. AD, AO, ML, and MS analyzed the data. AO, MS, and DC prepared the figures. ML, MT, EM, and OK worked on samples, library preparation, and sequencing. OB and DC designed and managed the entire study. MS and DC wrote the manuscript. All authors reviewed and approved the final manuscript.

FUNDING

This work was funded by Russian Science Foundation Project 14-14-00533.

ACKNOWLEDGMENTS

Cell sorting experiments were carried out using the equipment provided by the IBCH core facility (CKP IBCH, supported by Russian Ministry of Education and Science, grant RFMEFI62117X0018). Funding for open access publication: Skolkovo Institute of Science and Technology internal funding.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2018.02309/full#supplementary-material

REFERENCES

1. Castelo-Branco C, Soveral I. The immune system and aging: a review. Gynecol Endocrinol. (2014) 30:16–22. doi: 10.3109/09513590.2013.852531
2. DelaRosa O, Pawelec G, Peralbo E, Wikby A, Mariani E, Mocchegiani E, et al. Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology (2006) 7:471–81. doi: 10.1007/s10522-006-9062-6
3. Nikolich-Zugich J. Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. J Immunol. (2014) 193:2622–9. doi: 10.4049/jimmunol.1401174
4. Goronzy JJ, Fang F, Cavanagh MM, Qi Q, Weyand CM. Naive T cell maintenance and function in human aging. J Immunol. (2015) 194:4073–80. doi: 10.4049/jimmunol.1500046
5. Britanova OV, Shugay M, Merzlyak EM, Staroverov DB, Putintseva EV, Turchaninova MA, et al. Dynamics of individual T cell repertoires from cord blood to centenarians. J Immunol. (2016) 196:5005–13. doi: 10.4049/jimmunol.1600005
6. Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E, et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell (2009) 8:18–25. doi: 10.1111/j.1474-9726.2008.00443.x
7. Dunn-Walters DK. The ageing human B cell repertoire: a failure of selection? Clin Exp Immunol. (2016) 183:50–6. doi: 10.1111/cei.12700
8. Martin V, Bryan Wu YC, Kipling D, Dunn-Walters D. Ageing of the B-cell repertoire. Philos Trans R Soc Lond B Biol Sci. (2015) 370:20140237. doi: 10.1098/rstb.2014.0237
9. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine (2006) 24:1159–69. doi: 10.1016/j.vaccine.2005.08.105
10. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing (2007) 4:9. doi: 10.1186/1742-4933-4-9
11. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. Cytomegalovirus (CMV) seropositivity decreases B cell responses to the influenza vaccine. *Vaccine* (2015) 33:1433–9. doi: 10.1016/j.vaccine.2015.01.071

12. Frasca D, Diaz A, Romero M, Mendez NV, Landin AM, Blomberg BB. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season. *Immun Age* (2013) 10:14. doi: 10.1186/1742-493X-10-14

13. Pinti M, Appay V, Campisi J, Frasca D, Fulop T, Sauce D, et al. Aging of the immune system: focus on inflammation and vaccination. *Eur J Immunol*. (2016) 46:2286–301. doi: 10.1002/eji.201546178

14. Park S, Nahm MH. Older adults have a low capacity to opsonize pneumococcus due to low IgM antibody response to pneumococcal vaccinations. *Infect Immun*. (2011) 79:314–20. doi: 10.1128/IAI.00768-10

15. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. *Natt Rev Immunol.* (2009) 9:185–94. doi: 10.1038/nri2508

16. Del Giudice G, Weinberger B, Gruber-Kloezenstein B. Vaccines for the elderly. *Gerontology* (2015) 61:203–10. doi: 10.1159/000366162

17. Shelly MA, Jacoby H, Riley GI, Graves BT, Pichichero M, Trenor CJ. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. *Infect Immun*. (1997) 65:242–7.

18. Romero-Steiner S, Mushker DM, Cetron MS, Pais JB, Groover JE, Fiore AE, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. *Clin Infect Dis.* (1999) 29:281–8. doi: 10.1086/520200

19. Wolters B, Junde U, Dziuba S, Riggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. *Vaccine* (2003) 21:3623–8. doi: 10.1016/S0264-410X(03)00399-2

20. Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K, Agematsu K. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated earlier in life as well as on pre-vaccination antibody titers. *Vaccine* (2006) 24:6808–11. doi: 10.1016/j.vaccine.2006.06.037

21. Schenkin JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. *Vaccine* (2008) 26:25521–6. doi: 10.1016/j.vaccine.2008.07.071

22. Lord JM. The effect of ageing of the immune system on vaccine responses. *Hum Vaccin Immunother.* (2013) 9:364–7. doi: 10.4161/hv.24696

23. Vollmers C, Sit RV, Weinstein JA, Penland L, Sasaki S, He XS, et al. Lineage structure of the human antibody repertoire in response to influenza vaccination. *Sci Transl Med.* (2013) 5:171ra119. doi: 10.1126/scitranslmed.3004794

24. Greif V, Menzel U, Haessler U, Cook SC, Friedensohn S, Khan TA, et al. Quantitative assessment of the robustness of next-generation sequencing of antibody variable gene repertoires from immunized mice. *MBC Immunol.* (2014) 15:40. doi: 10.1186/s12865-014-0040-5

25. Laserson U, Vigneault F, Gadala-Maria D, Yaari G, Uduman M, Hoster E, et al. Booster vaccination in elderly with pre-existing antibodies: a case-control study. *Vaccine* (2014) 32:158–68. doi: 10.1016/j.vaccine.2013.09.007

26. Kaplanis J, Li A, Sun A, Coinje M, Korolov SB, Arnaout R. Antibody repertoire deep sequencing reveals antigen-independent selection in maturing B cells. *Proc Natl Acad Sci USA*. (2014) 111:4926–33. doi: 10.1073/pnas.1303261111

27. Georgiou G, Ippolito GC, Beausang J, Busse CE, Wardemann H, Quake SR. The promise and challenge of high-throughput sequencing of the antibody repertoire. *Nat Biotechnol.* (2014) 32:158–68. doi: 10.1038/nbt.2782

28. Friedensohn S, Khan TA, Reddy ST. Advanced methodologies in high-throughput sequencing of immune repertoires. *Trends Biotechnol.* (2017) 35:203–14. doi: 10.1016/j.tibtech.2016.09.010

29. Wang C, Liu Y, Xu LT, Jackson KJ, Roskin KM, Pham TD, et al. Effects of aging, *Cytomegalovirus* infection, and EBV infection on human B cell repertoires. *J Immunol*. (2014) 192:603–11. doi: 10.4049/jimmunol.1301384
51. Gupta NT, Vander Heiden JA, Uduman M, Gadala-Maria D, Yaari G, Kleinstein SH. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. *Bioinformatics* (2015) 31:3336–8. doi: 10.1093/bioinformatics/btv359

52. Egorov ES, Katsakaya SA, Zubov VN, Izraelson M, Nakonechnaya TO, Staroverov DB, et al. The changing landscape of naive T cell receptor repertoire with human aging. *Front Immunol.* (2018) 9:1618. doi: 10.3389/fimmu.2018.01618

53. Shugay M, Bagaev DV, Turchaninova MA, Bolotin DA, Britanova OV, Putintseva EV, et al. VDJtools: unifying post-analysis of T cell receptor repertoires. *PLoS Comput Biol.* (2015) 11:e1004503. doi: 10.1371/journal.pcbi.1004503

54. Kidera A, Konishi Y, Oka M. Statistical analysis of the physical properties of the 20 naturally occurring amino acids. *J Protein Chem.* (1985) 4:23–55. doi: 10.1007/BF01025492

55. Rackovsky S. Global characteristics of protein sequences and their implications. *Proc Natl Acad Sci USA.* (2010) 107:8623–6. doi: 10.1073/pnas.1001299107

56. Peng HP, Lee KH, Jian JW, Yang AS. Origins of specificity and affinity in antibody-protein interactions. *Proc Natl Acad Sci USA.* (2014) 111:E2656–65. doi: 10.1073/pnas.1401131111

57. Barak M, Zuckerman NS, Edelman H, Unger R, Mehr R. IgTree: creating Immunoglobulin variable region gene lineage trees. *J Immunol Methods* (2008) 338:67–74. doi: 10.1016/j.jim.2008.06.006

58. Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. *Front Immunol.* (2013) 4:302. doi: 10.3389/fimmu.2013.00302

59. Laffy JMJ, Dodev T, Macpherson JA, Townsend C, Lu HC, Dunn-Walters D, et al. Promiscuous antibodies characterised by their physico-chemical properties: from sequence to structure and back. *Prog Biophys Mol Biol.* (2017) 128:47–56. doi: 10.1016/j.pbiomolbio.2016.09.002

60. Padlan EA. Anatomy of the antibody molecule. *Mol Immunol.* (1994) 31:169–217. doi: 10.1016/0161-5890(94)90001-9

61. Tos JM, Meslin L, Pasqual G, Targ S, Jacobsen JT, Mano YM, et al. Visualizing antibody affinity maturation in germinal centers. *Science* (2016) 351:1048–54. doi: 10.1126/science.aad3439

62. Tabbikan-Kissir H, Hazanov L, Schiby G, Rosenthal N, Rakovsky A, Michaeli M, et al. Aging affects B-cell antigen receptor repertoire diversity in primary and secondary lymphoid tissues. *Eur J Immunol.* (2016) 46:480–92. doi: 10.1002/eji.20155586

63. Frasca D, Landin AM, Lechner SC, Ryan JG, Schwartz R, Riley RL, et al. Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. *J Immunol.* (2008) 180:5283–90. doi: 10.4049/jimmunol.180.8.5283

64. Bulati M, Caruso C, Colonna-Romano G. From lymphopoesis to plasma cells differentiation, the age-related modifications of B cell compartment are influenced by “inflamm-ageing.” *Aging Res Rev.* (2017) 36:125–36. doi: 10.1016/j.arr.2017.04.001

65. Labrie JE III, Borghesi L, Gerstein RM. Bone marrow microenvironmental changes in aged mice compromise V(DJ) recombinase activity and B cell generation. *Semin Immunol.* (2005) 17:347–55. doi: 10.1016/j.smim.2005.05.012

66. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. Age effects on B cells and humoral immunity in humans. *Aging Res Rev.* (2011) 10:330–5. doi: 10.1016/j.arr.2010.08.004

67. Banerjee M, Mehr R, Belolovsky A, Spencer J, Dunn-Walters DK. Age- and tissue-specific differences in human germinal center B cell selection revealed by analysis of IgVH gene hypermutation and lineage trees. *Eur J Immunol.* (2002) 32:1947–57. doi: 10.1002/1521-4141(200207)32:7<1947::AID-IMMU1947>3.0.CO;2-I

68. Troutaud D, Drouet M, Decourt C, Le Morvan C, Cogne M. Age-related alterations of somatic hypermutation and CDR3 lengths in human Vkappa4-expressing B lymphocytes. *Immunology* (1999) 97:197–203. doi: 10.1046/j.1365-2567.1999.00779.x

69. Khurana S, Frasca D, Blomberg B, Golding H. AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in vivo following pandemic 2009-H1N1 vaccination in humans. *PLoS Pathog* (2012) 8:e1002920. doi: 10.1371/journal.ppat.1002920

70. Frasca D, Diaz A, Romero M, Phillips M, Mendez NV, Landin AM, et al. Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. *Int Immunol.* (2012) 24:175–82. doi: 10.1093/intimm/dxr123

71. Miya Ji KT, Avelino-Silva VI, Simoes M, Freire MD, Medeiros CR, Braga PE, et al. Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults. *Rev Inst Med Trop Sao Paulo* (2017) 59:e2. doi: 10.1590/s1678-9946201759002

72. Vratskich O, Sisany K, Zlatkovic J, Tsouchnikas G, Garmer J, Karrer U, et al. Dissection of antibody specificities induced by yellow fever vaccination. *PLoS Pathog.* (2013) 9:e1003458. doi: 10.1371/journal.ppat.1003458

73. Collaborative group for studies on yellow fever vaccines. Duration of post-vaccination immunity against yellow fever in adults. *Vaccine* (2014) 32:4977–84. doi: 10.1016/j.vaccine.2014.07.021

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Davydov, Obratszova, Lebedin, Turchaninova, Staroverov, Merzlyak, Sharonov, Kladova, Shugay, Britanova and Chadakov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.